Clinical Trial Update: RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating a RANKL inhibitor to treat sarcopenia in elderly patients after hip fracture; recruitment has not yet begun.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcopenia

Snippet

Sponsor: Prince of Wales Hospital, Shatin, Hong Kong | Conditions: Sarcopenia in Elderly | Phase 3 | Status: NOT_YET_RECRUITING